BAMCO Inc
DNLI icon

BAMCO Inc’s Denali Therapeutics DNLI Stock Holding History

BAMCO Inc’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,500
Closed -$1.04M – 335
2024
Q1 		$1.04M Hold
50,500
– – ﹤0.01% 304
2023
Q4 		$1.08M Hold
50,500
– – ﹤0.01% 301
2023
Q3 		$1.04M Hold
50,500
– – ﹤0.01% 297
2023
Q2 		$1.49M Hold
50,500
– – ﹤0.01% 302
2023
Q1 		$1.16M Sell
50,500
-213,756
-81% -$5.88M ﹤0.01% 318
2022
Q4 		$7.35M Sell
264,256
-10,606
-4% -$316K 0.02% 245
2022
Q3 		$8.44M Sell
274,862
-843
-0.3% -$27.4K 0.03% 244
2022
Q2 		$8.11M Sell
275,705
-379,643
-58% -$9.94M 0.03% 258
2022
Q1 		$21.1M Sell
655,348
-340,956
-34% -$11.7M 0.05% 226
2021
Q4 		$44.4M Sell
996,304
-131,615
-12% -$6.24M 0.09% 176
2021
Q3 		$56.9M Sell
1,127,919
-127,305
-10% -$7.18M 0.13% 144
2021
Q2 		$98.5M Buy
1,255,224
+45,400
+4% +$2.81M 0.23% 97
2021
Q1 		$69.1M Buy
1,209,824
+146,418
+14% +$9.8M 0.17% 124
2020
Q4 		$89.1M Buy
1,063,406
+105,200
+11% +$6.36M 0.22% 95
2020
Q3 		$34.3M Buy
958,206
+5,249
+0.6% +$158K 0.11% 145
2020
Q2 		$23M Hold
952,957
– – 0.08% 162
2020
Q1 		$16.7M Hold
952,957
– – 0.08% 152
2019
Q4 		$16.6M Sell
952,957
-31,705
-3% -$528K 0.06% 176
2019
Q3 		$15.1M Hold
984,662
– – 0.06% 178
2019
Q2 		$20.4M Hold
984,662
– – 0.08% 171
2019
Q1 		$22.9M Buy
984,662
+760
+0.1% +$15.9K 0.1% 164
2018
Q4 		$20.3M Buy
983,902
+28,500
+3% +$517K 0.1% 162
2018
Q3 		$20.8M Buy
955,402
+9,940
+1% +$164K 0.09% 171
2018
Q2 		$14.4M Buy
945,462
+31,937
+3% +$602K 0.06% 188
2018
Q1 		$18M Buy
913,525
+423,525
+86% +$8.71M 0.08% 178
2017
Q4 		$7.66M Buy
+490,000
New +$8.81M 0.04% 211

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BAMCO Inc's DNLI Position: Q2 2024 in Review

BAMCO Inc sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 50,500 shares — an estimated $1.04M sold.

BAMCO Inc first reported a position in DNLI in Q4 2017 and held it in 26 quarters. The position peaked at $98.5M in Q2 2021. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • BAMCO Inc reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • BAMCO Inc sold 50,500 Denali Therapeutics shares in Q2 2024, an estimated $1.04M.
  • BAMCO Inc first reported a position in Denali Therapeutics in Q4 2017 and held it in 26 quarters.
  • BAMCO Inc's Denali Therapeutics position peaked at $98.5M in Q2 2021.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on BAMCO Inc's 13F filing for Q2 2024, filed 14 Aug 2024.